(1) pregnant or breast-feeding women, (2) ALT/AST > 5 times ULN, neutrophils < 0.5x10^9/L, platelets less than 50x10^9/L, (3) definite diagnosis of rheumatoid immunity, malignant tumor and other related diseases, (4) patients with long-term oral immunoregulatory drugs or who had used large doses of glucocorticoids within 14 days, (5) allergic reactions to adamumab or tozumab, (6) active hepatitis, tuberculosis, associated with specific severe bacterial and fungal infections, organ transplantation or mental disorders, (7) received Il-6 monoclonal antibody or TNFa monoclonal antibody within 14 days.

(1) pregnant or breast-feeding women, (2) ALT/AST > 5 times ULN, neutrophils < 0.5x10^9/L, platelets less than 50x10^9/L, (3) definite diagnosis of rheumatoid immunity, malignant tumor and other related diseases, (4) patients with long-term oral immunoregulatory drugs or who had used large doses of glucocorticoids within 14 days, (5) allergic reactions to adamumab or tozumab, (6) active hepatitis, tuberculosis, associated with specific severe bacterial and fungal infections, organ transplantation or mental disorders, (7) received Il-6 monoclonal antibody or TNFa monoclonal antibody within 14 days.